Pregabalin Versus Dexmedetomidine for Delirium Prevention After Cardiac Surgery

Launched by TANTA UNIVERSITY · Dec 6, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how effective two medications, pregabalin and dexmedetomidine, are in preventing delirium, which is a sudden change in mental status, in elderly patients after they have heart surgery. Delirium can cause confusion and is more common in older adults following surgery. The goal is to see which medication works better at reducing the chances of developing delirium and how long it lasts if it does occur.

To be eligible for this study, participants need to be at least 65 years old and scheduled for heart surgery. However, those with certain conditions, like a history of severe heart problems, psychiatric issues, or those unable to communicate, cannot take part. If someone joins the trial, they will receive either pregabalin or dexmedetomidine before and after their surgery. This research is important because it could help improve care for older patients undergoing heart surgery by finding better ways to prevent delirium.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III scheduled for cardiac surgery.
• Exclusion Criteria:
• • Patients who had history of psychiatric diseases; inability to communicate; previous history of POD; preoperative sick sinus syndrome.
• • Allergy/sensitivity to pregabalin or dexmedetomidine.
• • Severe bradycardia (heart rate \<50 beat per minute).
• • Second-degree or above atrioventricular block without pacemaker.
• • Severe hepatic or renal insufficiency.
• • Previous cardiac or thoracic surgery.
• • Known diagnosis of depression or other major psychiatric diseases.
• • Cognitive impairment or inability to cooperate with the study.
• • Renal insufficiency, and history of substance abuse.

Trial Officials